GBBWRPM
SVA

Genovese Burford & Brothers Wealth & Retirement Plan Management’s Sinovac Biotech, Ltd SVA Stock Holding History

Genovese Burford & Brothers Wealth & Retirement Plan Management’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-9,950
Closed -$59K – 533
2016
Q4 		$59K Hold
9,950
– – 0.02% 154
2016
Q3 		$58K Hold
9,950
– – 0.02% 147
2016
Q2 		$59K Hold
9,950
– – 0.02% 133
2016
Q1 		$63K Hold
9,950
– – 0.03% 111
2015
Q4 		$57K Buy
+9,950
New +$53.6K 0.03% 119

Other funds holding SVA

SA
SAIF Advisors Admiralty, Hong Kong $438M AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $359M AUM 23.01% 1-Year Est. Return
GP
GLG Partners London, United Kingdom $2.14B AUM 21.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Genovese Burford & Brothers Wealth & Retirement Plan Management's SVA Position: Q1 2017 in Review

Genovese Burford & Brothers Wealth & Retirement Plan Management sold out of Sinovac Biotech, Ltd (SVA) in Q1 2017, closing a stake of 9,950 shares — an estimated $59K sold.

Genovese Burford & Brothers Wealth & Retirement Plan Management first reported a position in SVA in Q4 2015 and held it in 5 quarters. The position peaked at $63K in Q1 2016. 35 funds tracked by Wall St. Rank hold SVA as of Q1 2017.

  • Genovese Burford & Brothers Wealth & Retirement Plan Management reported no remaining Sinovac Biotech, Ltd position as of Q1 2017 after selling out during the quarter.
  • Genovese Burford & Brothers Wealth & Retirement Plan Management sold 9,950 Sinovac Biotech, Ltd shares in Q1 2017, an estimated $59K.
  • Genovese Burford & Brothers Wealth & Retirement Plan Management first reported a position in Sinovac Biotech, Ltd in Q4 2015 and held it in 5 quarters.
  • Genovese Burford & Brothers Wealth & Retirement Plan Management's Sinovac Biotech, Ltd position peaked at $63K in Q1 2016.
  • 35 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q1 2017.

Based on Genovese Burford & Brothers Wealth & Retirement Plan Management's 13F filing for Q1 2017, filed 28 Apr 2017.